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Accepted goals of heart failure treatment include: 1) im-
provement in symptom status, 2) prevention of disease
progression, and 3) reduction in morbidity and mortality
(1). Complex pharmacologic therapies achieve these goals
for many, but not all, patients with heart failure. For
patients who remain symptomatic despite receiving “opti-
mal” medical therapy, novel adjunctive therapies are needed.
Technological advancements are permitting the exploration
of the so-called device therapies for heart failure. One such
device incorporates biventricular stimulation to resynchro-
nize cardiac contraction. The study by Stellbrink et al. (2) in
this issue of the Journal is consistent with other emerging
data finding that chronic resynchronization therapy may
achieve several treatment goals in heart failure including
symptom reduction and slowing of heart failure progression
(2–5).
See pages 1957 and 1966
Cardiac resynchronization therapy is only applicable to a
subset of heart failure patients, namely those with myocar-
dial conduction system delay. Myocardial conduction sys-
tem delay, manifest as bundle branch block, impacts 20% to
30% of New York Heart Association (NYHA) functional
class III–IV heart failure patients and consists predomi-
nately of left bundle branch block (6–9). The presence of
bundle branch block introduces contractile inefficiency and
dysynchrony, causing further diminishment of ventricular
function (9,10). When left ventricular (LV) conduction
delay is superimposed upon ventricular dysfunction, it
appears to be a marker of disease severity, predicting an
increased risk of both heart failure progression and suscep-
tibility to ventricular arrhythmias (11–15). Cardiac resyn-
chronization attempts to correct the deleterious effects of
dysynchrony. The question remains whether this approach
satisfies some or all heart failure treatment goals.
The echocardiographic data provided by Stellbrink et al.
(2) are derived from a subset of patients enrolled in one of
the first clinical studies of resynchronization therapy in
Europe, the Pacing Therapies in Congestive Heart Failure
(PATH-CHF) trial (2). Because of rapid advances in device
and lead technology, this trial differs from studies subse-
quently performed in Europe and the U.S., particularly in
relation to duration of follow-up and implant tools and
techniques. The PATH-CHF trial enrolled 42 patients
with advanced NYHA functional class III or IV heart
failure due predominately to nonischemic etiologies. Pri-
mary end points of the study were measures of functional
capacity. The PATH-CHF trial had a unique design,
common to two clinical trials of resynchronization therapy
performed in Europe (16). At the time of device implanta-
tion, subsequent programmed parameters were determined
on the basis of acute hemodynamic data measuring aortic
pulse pressure and dP/dt. Hemodynamics obtained in
sinus rhythm were compared with right, left and simulta-
neous biventricular stimulation performed at variable atrio-
ventricular intervals. Specifically, the hemodynamic data
were acquired, analyzed off-line and used to determine
whether resynchronization was chronically provided by right
ventricular, LV or simultaneous biventricular stimulation.
Patients enrolled in PATH-CHF had LV stimulation
provided from an epicardial LV lead placed via a limited
thoracotomy. Patients also received two separate pacemak-
ers and two endocardial right atrial leads to allow for
independent programming of right and left ventricle. In
contrast, all U.S. trials completed to date provided
resynchronization by simultaneous biventricular stimula-
tion (5). Patients were then paced for six months, at
which time echocardiography was performed and com-
pared to baseline.
The primary end points of the PATH-CHF trial were
positive, but they are not reported in the study by Stellbrink
et al. (2), and have only been published in abstract form
(17–19). The investigators do report that NYHA functional
class significantly improved over six months of resynchro-
nization therapy. The echocardiographic data demonstrate
improvements in LV volumes and dimensions, well-
validated measures of LV reverse remodeling. Neither LV
fractional shortening, mass, sphericity index nor heart rate
changed with therapy. There are no data evaluating the
effect of therapy on measures of diastolic function or right
heart function. Of interest, the beneficial effects of resyn-
chronization on LV volume and dimension did not correlate
with either acute hemodynamic or NYHA functional class
benefit. Also, there were patients who had progressive
ventricular enlargement on therapy but had improvement in
acute hemodynamic parameters and/or improvement in
functional class. This suggests that the well-described acute
hemodynamic benefit of LV or biventricular stimulation
may be uncoupled from the potential for a reverse ventric-
ular remodeling effect (20,21). It further suggests that
functional benefit can be seen in patients who do not attain
reverse remodeling. Accordingly, hemodynamic parameters
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may not be useful in determining the full potential of the
therapy to improve both symptom status and ventricular
remodeling.
Neither the study by Stellbrink et al. (2) nor a similar
study by Touiza et al. (22) in this issue of the Journal was
designed to answer whether chronic pacing of one ventricle
was equivalent to chronic simultaneous stimulation of both
ventricles. In the Stellbrink et al. (2) report, the site(s) of
stimulation was determined by the location that produced
the most favorable acute hemodynamic profile. In the
Touiza et al. (22) study, the stimulation site(s) was deter-
mined simply by physician preference, which in part was
influenced by individual patient anatomic characteristics
that dictated the practicalities of pacer lead placement. A
prospective, randomized trial will be needed to determine
whether single or biventricular stimulation is important in
achieving the treatment goals of chronic resynchronization
therapy.
Among other limitations of the Stellbrink et al. (2) study
is that the majority of patients had heart failure due to
idiopathic cardiomyopathy. The study results may not apply
to patients with an ischemic etiology for heart failure,
characterized by more regional myocardial dysfunction. As
there were changes in heart failure medications throughout
the study interval, this may have influenced LV volumes and
dimensions at six months independent of resynchronization.
Further, as only 60% of patients were receiving beta-
blockers, it is difficult to say whether chronic resynchroni-
zation is positively or adversely affected by chronic beta-
blockade. The Stellbrink et al. (2) study also attempted to
define a subgroup of “responders” to resynchronization (as
defined by a 15% decrease in LV end systolic volume
compared to baseline) and to determine whether baseline
characteristics of such patients were different from “nonre-
sponders.” The “responders” group, however, included pa-
tients whose LV end systolic volumes were stable following
resynchronization therapy and may themselves have differ-
ent baseline characteristics than true responders. Little can
therefore be said of this subgroup analysis.
Finally, although it is clear that the natural history of
heart failure is characterized by progressive myocardial
remodeling, studies of beta-blocker therapy that include a
control group find that some echocardiographic measures of
progression or regression of remodeling may not be detected
for up to 18 months. The study by Stellbrink et al. (2) may
be too short to understand the full impact (if any) of chronic
resynchronization therapy on myocardial remodeling (23).
Ever since the PATH-CHF study was initiated, device
technology has rapidly evolved. In the U.S., a resynchroni-
zation device has recently gained regulatory approval and a
resynchronization ICD is on the cusp of approval. Devices
are now available, on clinical protocol, that can be pro-
grammed to achieve resynchronization with LV or biven-
tricular stimulation, provide early diagnosis and treatment
of atrial arrhythmias, and offer real-time hemodynamic data.
All leads can now be implanted with a transvenous ap-
proach, thus avoiding thoracotomy. Left ventricular stimu-
lation is now achieved reliably and safely using a coronary
sinus branch vein (3,22,24–25). This is important as it
reduces the inherent operative morbidity and mortality of
thoracotomy in order to place the LV epicardial lead. One
patient died of postthoracotomy complications in the Stell-
brink et al. (2) study. The addition of defibrillation capa-
bility to the device adds little to device size or operative risk
(25). Thus, technologic advancements have rapidly im-
proved the safety and simplicity of LV lead placement.
Resynchronization devices may be simple and safe, but
does chronic resynchronization therapy fulfill its promise to
act as an adjunct to pharmacologic agents in the manage-
ment of heart failure patients with myocardial conduction
delay and achieve some or all of the goals of heart failure
treatment? In this calendar year, the results of the first
controlled clinical trials of resynchronization therapies pro-
viding six months of follow-up have been published or
presented (2,3,22,24–25). The data are consistent across
these studies, demonstrating the therapy’s effectiveness at
improving heart failure symptoms and stabilizing or reduc-
ing LV volumes and dimensions. Clinical trials initiated in
1999 are evaluating the ability of chronic resynchronization
therapy (with or without an ICD), compared to standard
medical therapies, to improve all-cause mortality and hos-
pitalization (4,26).
Those of us involved in the clinical studies of cardiac
resynchronization already appreciate that these devices pro-
mote optimal medical management of the heart failure
patient. Improvements in systolic blood pressure resulting
from resynchronization therapy allow for upward titration
of vasodilating drugs (22,25). The atrial rate support feature
is also very useful in this era of increasing use of beta-
receptor blocking agents. Although extremely attractive
theoretically, the mortality benefit of the defibrillating
capability is yet to be determined.
Why have technical devices been developed for cardiac
diseases? Simply put, because the need was there. The first
implantable pacemakers were devised by Chardack, Wilson,
and Greatbach in 1960 to treat heart block because medi-
cations were unable to correct this problem. The need was
there. The first ICD was proposed in 1966 by Mirowski
when a close friend experienced sudden death. Medications
were not preventing sudden death. The need was there.
Many heart failure patients still experience debilitating
symptoms and die prematurely despite “optimal” medical
therapy. The need for adjunctive therapy is here. The
development of resynchronization therapy is addressing this
need. The development of resynchronization therapy is a
unique cooperation of electrophysiologists and heart failure
pharmacotherapists that is only in its infancy. As Henry
Ford observed, “Coming together is a beginning; keeping
together is progress; working together is success.” The need
is here and success is our goal. We commend the early work
of Stellbrink et al. (2) for providing a rationale to establish
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resynchronization as a legitimate adjunctive therapy in the
management of heart failure.
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